Uncategorized Archives - Page 63 of 249

MondaySep 20, 2021 12:51 pm

RYAH Group Inc. (CSE: RYAH) Devices Ideal for Implementation of New Cannabis Intake Control Recommendations

Research team uses Delphi process for the first time to identify ideal cannabis dosing guidelines. After several rounds of voting, the ‘global task force’ created three separate dosing protocols. RYAH Group’s suite of precision dosing devices provide a practical way to safely execute these — or any — recommended dosing guidelines. Dosing recommendations are critical in any health treatments, but where cannabis is concerned, dosing levels have been tricky to identify. A recent blog from RYAH Group (CSE: RYAH) notes that a team of more than 20 cannabis experts have published consensus recommendations for dosing and administration of medical cannabis…

MondaySep 20, 2021 10:41 am

Sugarmade Inc. (SGMD) Ideally Positioned in Billion-Dollar Space ‘Ripe for Cannabis Delivery’

States that have already legalized cannabis are seeing a spike in business thanks to the overwhelming convenience of cannabis delivery Article reports that delivery services can “help surge revenue for retailers that jump in to take advantage” Earlier this year, SGMD launched a new business initiative for the licensed delivery of cannabis products According to a recent article, states that have already legalized cannabis, such as California, are seeing a spike in business thanks to the overwhelming convenience of cannabis delivery (https://cnw.fm/SrPtT). This is great news for Sugarmade (OTC: SGMD), an innovator in the dynamic California cannabis scene with majority…

FridaySep 17, 2021 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Signs Definitive Agreement to Acquire 100% of BayMedica Inc., Positioning it to Stand Distinct in Rare Cannabinoids Manufacturing, Become a Revenue-Generating Company, Expand Drug Development Capabilities

InMed Pharmaceuticals recently announced it has entered a definitive agreement to acquire 100% of BayMedica Inc. BayMedica is a private company that specializes in the manufacture and commercialization of rare cannabinoids Upon closing, the transaction will make InMed a global leader in the manufacturing of rare cannabinoids in addition to transforming it into a revenue-generating company Acquisition provides InMed with the complete flexibility across multiple manufacturing approaches On September 13, InMed Pharmaceuticals (NASDAQ: INM), a company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced it has signed a definitive agreement to acquire 100% of BayMedica…

FridaySep 17, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Draws Closer to NDA Filing for DehydraTECH CBD

Lexaria just released the most important results yet from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure Chris Bunka, Lexaria’s CEO, termed the results as “statistically significant” Participants in the study reported up to an average 23% decrease in blood pressure and a 7% drop in systolic pressure These results bring Lexaria closer to NDA filing with the FDA, making it a pioneer in CBD hypertension treatment Lexaria Bioscience (NASDAQ: LEXX) just released the most recent results from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s…

ThursdaySep 16, 2021 1:16 pm

Roth’s Investing in Women Cannabis Pioneers Investor Conference to Feature Female-Led Companies within the North American Cannabis Sector

Roth Capital Partners will host the “Women Cannabis Pioneers - The Brand Builders” event on September 28, 2021 The conference is set to feature approximately 25 privately held and female-led companies operating within the North American cannabis market Institutional investors will have an opportunity to discover new investment opportunities through their interaction with a host of emerging and lesser-known privately held companies Hosted by Roth Capital Partners (“Roth”), a widely respected independent securities research and trading firm specializing in emerging growth companies, the Investing in Women Cannabis Pioneers – The Brand Builders event has been uniquely designed to highlight the…

WednesdaySep 15, 2021 2:37 pm

Flora Growth Corp. (NASDAQ: FLGC) Receives its 2021 Commercial Export Quota Allocation from Colombian Government; Partners to Optimize Its Supply Chain By Implementing Global Cannabis Product Validation and Authentication Platform

Flora also recently announced it had received its 2021 commercial export quota allocation of 7,900 kilograms to cultivate, process, and distribute high-THC cannabis Flora Growth also announced it has entered into an agreement with Applied DNA Sciences, Inc. and TruTrace Technologies, Inc. FLGC will deploy the two companies’ integrated technology as part of its global cannabis product validation and authentication platform The integrated technology will tag, test, and track Flora’s cannabis and cannabis derivative products during transit across an international supply chain, providing enhanced transparency, traceability, and trust As an internationally focused company, Flora Growth (NASDAQ: FLGC) has always strived…

WednesdaySep 15, 2021 12:45 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Great Strides Toward Filing IND Application for Patented DehydraTECH(TM) Technology

Lexaria has begun the formal process of preparing an application for Investigational New Drug status for DehydraTECH(TM) and cannabidiol for hypertension The filing is being done with the assistance of an outside consultancy group, with Lexaria Bioscience designing non-clinical, clinical, and related product development required prior to the filing – all of which support Lexaria’s more ambitious goals There have been two successful human hypertension trials done with the combination DehydraTECH-CBD therapy in 2021, following an original human clinical study in 2018, and many animal studies Lexaria is making a strong case to support the efficacy of the technology for…

WednesdaySep 15, 2021 4:20 am

420 with CNW — BMW to Use Hemp, Hemp Materials to Reduce Emissions

The world’s leading manufacturer of premium motorcycles and automobiles, the BMW Group, seems focused on decreasing the emissions released when manufacturing and making use of its vehicles. It recently revealed that hemp would play a big role in this decrease in emissions. The company has been making use of hemp for a couple of years now in the door panel lining of its fully electric i3 model. The use of the plant in this way not only attracts eco-savvy consumers but also helps lighten the vehicle. Hemp, which is sometimes referred to as industrial hemp, is a class of cannabis…

TuesdaySep 14, 2021 4:20 pm

420 with CNW — AMA Study Shows Cannabis Legalization Hasn’t Increased Youth Marijuana Use

When cannabis drug reform was just starting to gain steam, many a prohibitionist argued that legalizing cannabis would increase access and directly lead to an increase in marijuana use by the youth. However, things have played out differently, with most states having legal cannabis markets reporting no increase in youth drug use after they launched recreational or medical cannabis sales. A new study on adolescent cannabis consumption that was recently published in a prominent scientific journal has now joined the growing body of literature that has found no correlation between the emergence of recreational and cannabis laws and an increase…

MondaySep 13, 2021 3:02 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Impressive Blood Pressure Reduction in Hypertension Clinical Trials

Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing Lexaria’s patented DehydraTECH (TM) technology is undergoing human clinical trials this year to determine its effectiveness in making cannabidiol (“CBD”) effective as a means of reducing blood pressure for high blood pressure patients The initial results of the first human clinical study showed the DehydraTECH-CBD compound was well tolerated by patients without troubling side effects and that the compound outperformed generic CBD controls Just-released initial (partial) results regarding the compound’s second human clinical trial show that a three-dose regimen…

News and publishing service for cannabis related companies

Contact us: 512.354.7000

Category: Uncategorized